The vascular endothelial growth factor (VEGF) signaling pathway appears to be the
dominant pathway involved in tumor angiogenesis, providing a rationale for targeting the …

Purpose To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …

Therapies that target the vascular endothelial growth factor (VEGF) pathway cause
hypertension, but the mechanism remains unknown. This cross-sectional study tested the …

Vascular endothelial growth factor (VEGF) pathway activation leads to the angiogenic
phenotype of renal cell carcinoma (RCC). Several different strategies targeting various …

The introduction of molecularly targeted anticancer therapies has brought the promise of
longer survival times for select patients with cancers previously considered untreatable …

Angiogenesis is required for tumor growth and metastasis and, therefore, represents an
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …

Drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are a
rapidly growing chemotherapy class for treatment of solid tumors. This targeted therapy is …

The perception that inhibition of cancer-associated angiogenesis would be an effective
treatment strategy was based on the fundamental difference in cell cycle activity between …

VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma,
gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a …

Anti-angiogenic therapy in cancer has become very popular. Agents inhibiting new vessel
formation (angiogenesis) and blood supply can have anticancer effects. This idea …